Confirmed Control (12%) Closed Transaction verified Consumer Healthcare Healthcare OTC medicines Pharma

Tianjin TSKF Pharmaceutical Co., Ltd. acquired by Haleon plc

Haleon plc acquired Tianjin TSKF Pharmaceutical Co., Ltd., a Chinese pharma brand, on Jun 27, 2025.

Transaction summary

Target: Tianjin TSKF Pharmaceutical Co., Ltd.
Acquirer: Haleon plc
Seller: Tianjin Pharmaceutical Da Ren Tang Group (DRTG)
Announced: -
Geography: China
Tags: Consumer Healthcare Healthcare OTC medicines Pharma
Type: Acquisition
Deal type: Control
Stake acquired: 12%
First added: 2026-10-18
Latest update: 2026-10-18

Value and multiples

100% enterprise value

Undisclosed

Value not disclosed

Basis: FundComb estimate

Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.

EV / revenue

Period not stated

Basis: FundComb estimate

EV / EBITDA

EBITDA basis not stated

Basis: FundComb estimate

Basis

Enterprise value is unavailable.

Source summary

Haleon 20-F, filed 2026-03-13

Confirmed

Acquisition of Tianjin TSKF Pharmaceutical Co., Ltd. by Haleon plc.

Open source

Haleon 20-F, filed 2026-03-13

Confirmed

Our strategic position in China, our second-largest market and a key source of long-term growth, was advanced through the acquisition of the remaining 12% stake in our TSKF joint venture.

Open source

Haleon 20-F, filed 2026-03-13

Confirmed

Monitored the completion in Haleon’s acquisition of the remaining 12% shareholding in TSKF.

Open source

Haleon 20-F, filed 2026-03-13

Confirmed

Haleon plc becomes 100% free float following Pfizer Inc. final sell down of shares and previous GSK sell down. Completed acquisition of TSKF joint venture GSK ownership

Open source